Loading…
Employees: 489
Size Beijing Science Sun Pharmaceutical (300485.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $566M, the 3569th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.83 on 6 Nov 2026.
Performance Over six months the shares fell 28.2%, against -14.1% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 10.6% over the last twelve months (peer median +6.4%); the operating margin is -8.2% (peer median 6.4%).
Valuation It trades at 6.5× enterprise value to sales against a peer median of 4.0× (5th most expensive of 19).
Capital Return on invested capital runs 6.1 points below its cost of capital (6.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥359M | CN¥401M | CN¥415M | CN¥474M | CN¥730M |
| Revenue growth | — | -3% | -13% | -35% | — |
| Gross profit | CN¥255M | CN¥244M | CN¥258M | CN¥317M | CN¥542M |
| EBITDA | n/a | CN¥30.1M | CN¥69.9M | CN¥8.45M | CN¥71.4M |
| Net income | -CN¥167M | CN¥14.6M | -CN¥68.9M | CN¥103M | CN¥205M |
| Free cash flow | -CN¥52.1M | -CN¥30.9M | CN¥60.1M | -CN¥16.1M | CN¥107M |
| Capital expenditure | CN¥90.7M | CN¥100M | CN¥101M | CN¥52.9M | CN¥43.3M |
| Total debt | CN¥29.0M | CN¥19.7M | CN¥0 | CN¥0 | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300485.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.6% | -9.7% | 9th highest of 21 |
| 6-month return | -28.2% | -14.1% | 6th lowest of 21 |
| Distance from 52-week high | -43.3% | -32.4% | 6th lowest of 21 |
| Revenue growth (TTM) | -10.6% | +6.4% | 4th lowest of 20 |
| Operating margin | -8.2% | 6.4% | 5th lowest of 19 |
| EV / Sales | 6.5× | 4.0× | 5th most expensive of 19 |
| ROIC minus cost of capital | -6.1 pp | -1.5 pp | 5th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |